openPR Logo
Press release

US Cancer Generics Market Outlook 2022 Report

05-07-2018 06:07 AM CET | Health & Medicine

Press release from: Kuick Resarch

“US Cancer Generics Market Outlook 2022” report highlights:

* Introduction to Cancer Generics
* US Generic Drugs Legislature
* US Health Insurance Scenario and Cancer
* Aspects of Branded and Non-Branded Generics
* US Cancer Generics Market Overview

Download Report Sample Weblink:

https://www.kuickresearch.com/report-us-cancer-generics-market-outlook-2022.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

Cancer Generics: A Modest Regimen
1.1 Introduction to Cancer Generics
1.2 Why There Exist is Need for Generic Forms?
1.3 Supremacy of Cancer Generic Drugs
1.3.1 Cost
1.3.2 Quality and Safety
1.3.3 Large Number of Manufacturer
1.3.4 Approved by FDA
1.3.5 Concerns in Cancer Generic Medication

US Generic Drugs Legislature
2.1 Hatch-Waxman Act, 1984
2.2 The Generic Drugs Chronological Disgrace

Trail towards Patenting of Cancer Generic Drugs
3.1 US Generic Pharmaceutical Regulation
3.2 Patenting Wars of Cancer Generics in US

Economic Burden of Prescription Drugs in US
4.1 High Cost of Cancer Drugs
4.2 Healthcare Savings by Virtue of Generics

Cancer Generic Drugs: Still Overpriced in US Market
5.1 Innovation is Meaningless if Nobody can Afford It
5.2 Why US Contends More in Generics?

US Health Insurance Scenario and Cancer
6.1 Provisions for Cancer Drug Coverage
6.2 Private Health Insurance Options
6.3 Government Funded Insurance

Aspects of Branded and Non-Branded Generics
7.1 Debut of Authorized Generics in Market
7.2 Anti-Authorized Generic Legislation

Generics in Oncology World
8.1 Anti-Cancer Targeted Therapy Drugs
8.2 Status of Generics in Monoclonal Antibodies
8.3 Crusade of Small Molecule Inhibitor towards Generics

FDA Approved Anti-Cancer Generics in US
9.1 Taxotere (Generic Docetaxel)
9.2 Imatinib (Generic Glivec)
9.3 Sorafinib ( Generics Nexavar)

US Cancer Generics Market Overview
10.1 US Cancer Generics Market Introduction
10.2 Europe Generics Market Contrary to US
10.3 Asia Generics Market Contrary to US

Cancer Generics Drug Market Dynamics
11.1 Accelerative Parameters
11.1.1 Expiration of Patents
11.1.2 Unaffordability of Cancer Drugs
11.1.3 Cost Containment by Government
11.1.4 Generic Drug User Fee Amendments (2012)
11.1.5 High Cancer Risk and Aging Population of US
11.2 Pitfalls Confronted by Generic Industry

US Cancer Generics Market Future Prospect

Figure 1-1: US - Savings through Generic Drug usage (US$ Billion), 2010-2015
Figure 1-2: Zofran- Price of Branded and Generic Pill (US$)
Figure 1-3: Illustration of Pros and Cons of Generic Drugs
Figure 2-1: Interests of Brand drug and Generic Drug Industry over Hatch-Waxman Act
Figure 3-1: Major Exclusivity under the NDA Statutory Requirements
Figure 3-2: Demonstration of Bringing Generic Drug into Market
Figure 3-3: US - FDA Rules for Generics Production
Figure 4-1: Branded V/S Generic Prescription Drug Revenues (2005-2015)
Figure 4-2: US andndash; Expected Cost Savings through Generics in Cancer Therapy (US$ Billion), 2016-2022
Figure 4-3: US - Potential Cost Saving Across Biologics in
Figure 5-1: US - Representation of Generic Cost of Gleevac
Figure 6-1: Distribution of Medicare Savings in FY2016 Budget
Figure 6-2: Cost Sharing of Generic Drug in Medicare Part D Coverage Gap (%), 2015-2020
Figure 6-3: Various Medicare Beneficiaries Provided by US Government
Figure 6-4: US - Share of Medicare and Self Payment for Generics Drug (%)
Figure 7-1: Illustration of the Profits Earned During the 180-Day Exclusivity
Figure 7-2: Strategies for Launching Authorized Generics in Market
Figure 8-1: US - Proportion of Branded and Generic Drug Revenues (%), 2010-2015
Figure 8-2: FDA Approved Monoclonal Antibodies in Cancer Therapeutics
Figure 8-3: Development Cost of Generics v/s Biosimilar
Figure 9-1: Cost Comparison of Gleevac in Branded and Generic Versions
Figure 9-2: Naxawar Price Difference in Generic and Branded Version
Figure 10-1: Global - Top Generics Manufacturers Based on Revenues (US$ Billion), 2015
Figure 10-2: US andndash; Generics Drug Market Opportunity (US$ Billion). 2016-2022
Figure 10-3: US - Savings through Generic Drug Usage (US$ Billion), 2017-2022
Figure 10-4: US - Share of Leading Generic Companies
Figure 11-1: Major Accelerative Parameters for the Growth of Generic Market
Figure 11-2: Current Challenges Faced by Generic Pharmaceutical

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release US Cancer Generics Market Outlook 2022 Report here

News-ID: 1040659 • Views: 231

More Releases from Kuick Resarch

Global Cell Therapy Market To Surpass US$ 400 Billion In Opportunity By 2027 Wit …
"Global Cell Therapy Market, Therapy Price, Dosage & Clinical Trials Insight 2027" Report Highlights: • Global Cell Therapy Market Opportunity: More Than USD 40 Billion By 2027 • Cell Therapy Clinical Trial Insight by Indication, Company and Country • Global Cell Therapy Clinical Pipeline: 1000 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Cell Therapy Trials For COVID-19: 10 Cell Therapies • Global COVID-19 Cell Therapy Clinical Trials By Phase & Company • COVID-19 Impact Analysis on Global market &
Global Cancer Immunotherapy Market Offers US$ 200 Billion Opportunity With 2300 …
"Global Cancer Immunotherapy Market Opportunity, Dosage, Price & Clinical Trials Insight 2026" Report Highlights: • Global Cancer Immunotherapy Market Opportunity: > US$ 200 Billion • Cancer Immunotherapy Clinical Trials: > 2300 Drugs In Trials • Commercially Available Cancer Immunotherapies: > 120 • Cancer Vaccines Market Opportunity: > US$ 20 Billion • Cancer Monoclonal Antibodies Market Opportunity: > US$ 90 Billion • Marketed Cancer Monoclonal Antibodies': > 70 mAbs • Sales, Market Opportunity, Dosage & Price Data: 300 Graphs/Charts • Clinical Trials Insight By Phase,
Global Cell Therapy Market, Therapy Price, Dosage Clinical Trials 2027
"Global Cell Therapy Market, Therapy Price, Dosage & Clinical Trials Insight 2027" Report Highlights: • Global Cell Therapy Market Opportunity: More Than USD 40 Billion By 2027 • Cell Therapy Clinical Trial Insight by Indication, Company and Country • Global Cell Therapy Clinical Pipeline: 1000 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Cell Therapy Trials For COVID-19: 10 Cell Therapies • Global COVID-19 Cell Therapy Clinical Trials By Phase & Company • COVID-19 Impact Analysis on Global market &
Global Cell Therapy Market, Therapy Price, Dosage & Clinical Trials Insight 2027
"Global Cell Therapy Market, Therapy Price, Dosage & Clinical Trials Insight 2027" Report Insight: * Market Opportunity: >USD 40 Billion * Clinical Trial Insight: > 1000 Cell Therapies * COVID-19 Impact Analysis on Global Cell Therapy Market * Cell Therapies For COVID-19: > 10 Cell Therapies * Marketed Cell Therapies: 25 Cell Therapies Download Report: https://www.kuickresearch.com/report-global-cell-therapy-market,-therapy-price,-dosage-and-clinical-trials-insight-2027.php Table of Contents 1. Overview of Cell Therapy 1.1 Introduction to Cell Therapy 1.2 History & Evolution of

All 5 Releases


More Releases for Generic

A Demand On Generic Drugs Market And The Need To Push The Market Of Generic Drug …
Global Generic Drugs Market A generic drug is pharmaceutical drug, which is bio-equivalent to a branded drug in all forms such as route of administration, strength, dosage, quality, intended use and performance. Generic drugs are usually approved after patent expiration of patent drugs. Generic drugs are safe, effective and FDA approved. The global market is filled with 44% of generic drugs. The global generic drugs market is driven by the rise of
Generic Drugs Market - Global Competitive Analysis
Generic drugs market growth is buoyed by increasing number of patented expiries for drugs each year. According to the IMS data small-molecule products worth US$ 121 Bn are expected to lose patents in developed markets, such as U.S and Europe between 2014 and 2018. The IMS also forecasts that biologic products valued at US$ 48 Bn are expected to lose patent protection over the next three years i.e from 2017
Generic Drugs Market Trends 2025
Generic drugs market growth is buoyed by increasing number of expiries of patented drugs each year. According to the IMS data small-molecule products worth US$ 121 Bn are expected to lose patents in developed markets, such as U.S ad Europe between 2014 and 2018. The IMS also forecasts that biologic products valued at US$ 48 Bn are expected to lose patent protection over the next three years i.e from 2017
Global Generic Drugs Market Research Report 2017
In this report, the global Generic Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Generic Drugs in these regions, from 2012 to 2022 (forecast), covering North
Generic Drugs: Global Collaboration Opportunities
Collaboration is the key to growth With the recent economic turmoil affecting many markets around the world, the generic and branded sectors face similar problems. At one time the generic sector was seen as a valuable way to bring effective products to a wider audience. This, allied to the rising cost of new advanced branded products, led to rapid expansion of the generics sector. Even markets traditionally based in the provision of
Generic Drugs: Global Collaboration Opportunities
Collaboration is the key to growth With the recent economic turmoil affecting many markets around the world, the generic and branded sectors face similar problems. At one time the generic sector was seen as a valuable way to bring effective products to a wider audience. This, allied to the rising cost of new advanced branded products, led to rapid expansion of the generics sector. Even markets traditionally based in the provision of